J&J: positive results in generalized myasthenia gravis

(CercleFinance.com) - Johnson & Johnson reports that The Lancet Neurology has published the results of a Phase 3 study of nipocalimab, evaluated in a large population of antibody-positive adults (anti-AChR+, anti-MuSK+, anti-LRP4+) with generalized myasthenia gravis (gMG).


The laboratory reports that the study met its primary endpoint, demonstrating a statistically and clinically significant improvement over 24 weeks in the so-called 'MG-ADLa' score.

Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation rates similar to placebo (5.1% with nipocalimab vs. 7.1% with placebo).

"The positive results of the study reinforce the potential of nipocalimab to treat the underlying cause of this debilitating autoimmune disease," said Carlo Antozzi, of the Neuroimmunology and Muscle Pathology Unit at the C. Besta Foundation Neurological Institute in Milan. Besta Neurological Institute in Milan.

As a reminder, gMG is a rare, chronic, lifelong disease caused by autoantibodies, for which there is currently no cure.


Copyright (c) 2025 CercleFinance.com. All rights reserved.